
Minerva Neurosciences (NERV) Stock Forecast & Price Target
Minerva Neurosciences (NERV) Analyst Ratings
Bulls say
Minerva Neurosciences is well-positioned for success with its promising product candidate, roluperidone, which has shown effectiveness and safety in Phase 2b and 3 trials. Market research indicates significant demand for treatment of negative symptoms of schizophrenia, and the company's Phase 3 trial design has been aligned with the FDA. With a strong financial standing and potential for global expansion upon positive results, Minerva is poised for future growth and success in the CNS disease treatment market.
Bears say
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development of Roluperidone, a small molecule antagonist of serotonin 5-HT2A, sigma2, and α1A-adrenergic receptors being developed to treat negative symptoms of schizophrenia. However, the company's stock has a negative outlook due to mixed results from its pivotal trials, increased competition from other biopharmaceutical companies, and the potential for a high placebo effect in its ongoing Phase 3 study. The company's potential for success is further limited by a small target market and the potential for adverse effects commonly associated with antipsychotic drugs.
This aggregate rating is based on analysts' research of Minerva Neurosciences and is not a guaranteed prediction by Public.com or investment advice.
Minerva Neurosciences (NERV) Analyst Forecast & Price Prediction
Start investing in Minerva Neurosciences (NERV)
Order type
Buy in
Order amount
Est. shares
0 shares